A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 9, 2025

Primary Completion Date

August 24, 2029

Study Completion Date

August 24, 2029

Conditions

CHAPLE Disease

Interventions

DRUG

Pozelimab

Administered per the protocol

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY